Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
News|Articles|August 27, 2026
What Heidi Overton's FDA Nomination Could Mean for Pharmacy
Author(s)Luke Halpern, Associate Editor
Fact checked by: Kennedy Ferruggia, Associate Editor, Kirsty Mackay
If Heidi Overton is confirmed, the FDA nominee's views on abortion pills, vaccines, and drug review could reshape pharmacists' daily work.
Advertisement
Advertisement
President Donald Trump’s nomination of Heidi Overton, MD, PhD, to lead the FDA sets up a confirmation fight whose outcome could touch nearly every corner of the pharmacy—from how mifepristone is dispensed to whether childhood vaccines arrive as combination shots or individual doses. For pharmacists, the more consequential story is not the nomination itself but what an Overton-led FDA would mean at the counter, the point at which agency policy becomes a dispensing decision.1,2
Related to this article
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Advertisement
Advertisement